Christopher Whitlow, MD, PhD, MHA
Chair, Department of Radiology and Biomedical ImagingAbout
Research
Publications
2025
Comparative Analysis of AI-based Quantification vs. Visual Rating of Enlarged Perivascular Spaces in the MESA Cohort.
Torres M, Charisis S, Rashid T, Brandigampala S, Hiatt K, Ware J, Whitlow C, Nasrallah I, Romero J, Tanley J, Seshadri S, Hohman T, Heckbert S, Davatzikos C, Hughes T, Habes M. Comparative Analysis of AI-based Quantification vs. Visual Rating of Enlarged Perivascular Spaces in the MESA Cohort. American Journal Of Neuroradiology 2025, ajnr.a9129. PMID: 41397892, DOI: 10.3174/ajnr.a9129.Peer-Reviewed Original ResearchMulti-Ethnic StudyMulti-Ethnic Study of AtherosclerosisVascular risk factorsCross-sectional studyStudy of atherosclerosisSystolic blood pressureRisk factorsWaist-to-hip ratioAssociated with higher systolic blood pressureDomain-specific cognitive scoresAssociation of perivascular spacesHigher systolic blood pressurePoorer global cognitionAssociated with older ageLarge-scale epidemiological dataOrdinal logistic regressionCognitive performanceBlood pressureWhite race/ethnicityGlobal cognitionOdds ratioSelf-ReportBasal gangliaLogistic regressionDemographic characteristicsA large scale multi-dataset investigation of brain metastases distribution based on primary cancer type
Lyu Q, Yuan H, Lin Z, Barcus R, Hudson J, Jiang Y, Kim J, Whitlow C. A large scale multi-dataset investigation of brain metastases distribution based on primary cancer type. BMC Cancer 2025, 25: 1821. PMID: 41291518, PMCID: PMC12648834, DOI: 10.1186/s12885-025-15222-5.Peer-Reviewed Original ResearchCancer brain metastasesBreast cancer brain metastasesBrain metastasesPattern of brain metastasesLung cancer brain metastasisMelanoma brain metastasesPrimary tumor typePrimary cancer typeTemporal lobeMetastasis distributionTumor volumeTumor typesPoor prognosisKidney cancerClinical challengeHeterogeneous distribution patternCancer typesMelanomaStatistical differenceBreastLungKidneyFrontal lobeLongitudinal measures of monkey brain structure and activity through adolescence predict cognitive maturation
Zhu J, Garin C, Qi X, Machado A, Wang Z, Ben Hamed S, Stanford T, Salinas E, Whitlow C, Anderson A, Zhou X, Calabro F, Luna B, Constantinidis C. Longitudinal measures of monkey brain structure and activity through adolescence predict cognitive maturation. Nature Neuroscience 2025, 28: 2344-2355. PMID: 41145886, PMCID: PMC12586175, DOI: 10.1038/s41593-025-02076-0.Peer-Reviewed Original ResearchConceptsNeural activityCognitive performanceBrain structuresAdolescent neurocognitive developmentPrefrontal neural activityWorking memory improvementNeural activity changesLongitudinal studyAdolescent cognitive developmentWhite matter tractsMemory improvementBrain areasCognitive abilitiesCognitive changesCognitive maturityBrain volumeFrontal lobeCognitive developmentAssociated with improvementsNeurocognitive developmentNeuronal activityComplex aspectsLongitudinal measurementsActivity changesBaseline rateTreatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields
Jimenez H, Gibo D, Sharma S, Pennison M, Miller L, Wang M, Sheffield K, Zhang L, Johansen A, Achari P, Mcgrath C, Lester S, Tang J, Agyemang K, Johnson A, Whitlow C, Chan M, Watabe K, D’Agostino R, Liyanage J, Azmi A, Barger G, Barbault A, Lesser G, Debinski W, Pasche B. Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields. Oncotarget 2025, 16: 741-757. PMID: 41081453, PMCID: PMC12517218, DOI: 10.18632/oncotarget.28770.Peer-Reviewed Original ResearchConceptsCell linesIdentical to patientsCompassionate use treatmentKinase pathwayTreatment of glioblastomaEvidence of safetyRecurrent GBGB cell linesSystemic deliveryClinical activityIntrabuccal administrationRadiofrequency electromagnetic fieldsBrain tumorsMechanism-of-actionPatientsAntitumor activityRadiological benefitGlioblastomaOligodendrogliomasTreatmentUse treatmentRF-EMFMitotic spindleCellular assaysPathwayA phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD
Erichsen J, Register T, Sutphen C, Ma D, Gaussoin S, Rudolph M, Rundle M, Bateman J, Lockhart S, Sai K, Whitlow C, Craft S. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD. Alzheimer's & Dementia 2025, 21: e70704. PMID: 41057918, PMCID: PMC12504051, DOI: 10.1002/alz.70704.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsCerebral blood flowIntranasal insulinSodium-glucose cotransporter-2 inhibitor empagliflozinFractional anisotropyMarkers of vascular injuryMarkers of inflammationGlial fibrillary acidic proteinFibrillary acidic proteinInhibitor empagliflozinEmpagliflozin treatmentSodium-glucoseAdverse eventsPlasma glial fibrillary acidic proteinRandomized trialsEmpagliflozinPrimary outcomeVascular injurySecondary outcomesVascular disordersImaging biomarkersImmune functionBlood flowInsulinAcidic proteinPredicting Immunotherapy-Induced Pneumonitis Based on Chest CT and Non-Imaging Data
Lyu Q, Yuan H, Lin Z, Ponnatapura J, Whitlow C. Predicting Immunotherapy-Induced Pneumonitis Based on Chest CT and Non-Imaging Data. Cancers 2025, 17: 2980. PMID: 41008824, PMCID: PMC12468472, DOI: 10.3390/cancers17182980.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsICI-pneumonitisCT scanTreatment of non-small cell lung cancer patientsComputed tomographyNon-small cell lung cancer patientsRisk of developing pneumonitisCell lung cancer patientsHigh riskICI-based immunotherapyImmunotherapy-induced pneumonitisEarly identification of patientsSignificant survival benefitScreening computed tomographyEarly identificationIdentification of patientsReceiver operating characteristic curveArea under the receiver operating characteristic curveLung cancer patientsOperating characteristics curveCheckpoint inhibitorsChest CTSurvival benefitClinical featuresClinical dataStructural Alterations in the Gray Matter Volume in Rapid‐Onset Dystonia‐Parkinsonism
Haq I, Simonyan K, Napoli E, Ozelius L, Snively B, Whitlow C, Sweadner K, Brashear A. Structural Alterations in the Gray Matter Volume in Rapid‐Onset Dystonia‐Parkinsonism. Movement Disorders 2025, 40: 2510-2516. PMID: 40888012, PMCID: PMC12661632, DOI: 10.1002/mds.30320.Peer-Reviewed Original ResearchGray matter volumeMatter volumeWhole-brain gray matter volumeRight inferior temporal cortexStructural magnetic resonance imaging dataGray matter volume changesExecutive brain regionsPrefrontal cortical volumeRDP patientsInferior parietal cortexRight prefrontal cortexInferior temporal cortexParkinson's diseaseBilateral caudate nucleusMagnetic resonance imaging dataThalamic blood flowPrefrontal cortexFusiform gyrusTemporal cortexParietal cortexBrain regionsCaudate nucleusCortical volumeMatter organizationRapid-onset dystonia-parkinsonismGenomic Signature to Predict Neurologic Death in Non-Small Cell Lung Cancer Patients
Glynn S, Lanier C, Choi A, D'Agostino R, Farris M, Abdulhaleem M, Wang Y, Smith M, Ruiz J, Lycan T, Petty W, Cramer C, Tatter S, Laxton A, White J, Su J, Whitlow C, Xing F, Chan M, Helis C. Genomic Signature to Predict Neurologic Death in Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e264-e265. DOI: 10.1016/j.ijrobp.2025.06.2116.Peer-Reviewed Original ResearchNon-small cell lung cancerNon-small cell lung cancer patientsRisk of neurological deathBrain metastasesLow-risk groupNeurological deathNon-neurologic deathRisk groupsHazard ratioNext-generation sequencingRisk scoreCumulative incidenceCumulative incidences of neurological deathAssociated with neurological deathIncidence of neurologic deathCell lung cancer patientsHigh riskNext-generation sequencing panelSystemic therapy regimensAggressive local therapyCell lung cancerNon-invasive liquid biopsyModerate risk groupProportional hazards regression modelsProgressive neurological dysfunctionOptimizing Blood-Based Genomic Characterization of Oligometastatic Non-Small Cell Lung Cancer Patients
Choi A, Lanier C, Glynn S, Young P, D'Agostino R, Farris M, Abdulhaleem M, Wang Y, Ruiz J, Lycan T, Petty W, Cramer C, Tatter S, Laxton A, White J, Li W, Su J, Whitlow C, Xing F, Chan M. Optimizing Blood-Based Genomic Characterization of Oligometastatic Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: s199-s200. DOI: 10.1016/j.ijrobp.2025.07.1291.Peer-Reviewed Original ResearchNon-small cell lung cancerOligometastatic non-small cell lung cancerCohort of NSCLC patientsHigh-risk scoreNSCLC patientsOverall survivalLow-risk scoresOligometastatic diseaseBrain metastasesRisk scoreCumulative incidenceValidation cohortManagement of oligometastatic non-small cell lung cancerNon-small cell lung cancer patientsHazard ratioCell lung cancer patientsExtracranial oligometastatic diseaseInstitutional patient databaseCirculating tumor DNACell lung cancerCox regression analysisMantel-Haenszel chi-square testFisher's exact testLung cancer patientsOligometastatic phenotypePrediction of Oligometastatic Disease from Breast Cancer Using Next Generation Sequencing Genomics
Young P, Choi A, Hunting J, Ormond S, Wang Y, Douglas E, Ansley K, Cramer C, Li W, Whitlow C, Xing F, Soto-Pantoja D, Ruiz J, Chan M. Prediction of Oligometastatic Disease from Breast Cancer Using Next Generation Sequencing Genomics. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e233-e234. DOI: 10.1016/j.ijrobp.2025.06.3806.Peer-Reviewed Original ResearchOligometastatic diseaseOligometastatic progressionBreast cancerRisk scoreNext generation sequencingCumulative incidenceWidespread progressionWidespread diseaseMetastatic breast cancerFisher's exact testMetastatic diseaseChi-square testExtracranial diseaseDiffuse involvementWald chi-square testExact testCox regressionPatientsMedical recordsElectronic medical recordsStandard panelCancerPatients' scoresDiseaseSequenced genomes